Roivant Sciences Ltd. (ROIV) is a Biotechnology company in the Healthcare sector, currently trading at $29.12. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.
Analyst consensus target is ROIV = $32 (+8.2% upside).
Valuation: ROIV trades at a trailing Price-to-Earnings (P/E) of -24.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.96.
Financials: revenue is $29M, +12.6%/yr average growth. Net income is $172M (loss), growing at +135.9%/yr. Net profit margin is -592% (negative). Gross margin is 96.9% (+13.1 pp trend).
Balance sheet: total debt is $100M against $4.7B equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 33.47 (strong liquidity). Debt-to-assets is 1.8%. Total assets: $5.4B.
Analyst outlook: 13 / 14 analysts rate ROIV as buy (93%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 68/100 (Pass), Growth 90/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 68/100 (Partial), Future 88/100 (Pass), Income 10/100 (Fail).
